Douglas Lind

Douglas Lind

President chez
TMune Therapeutics, Inc.
66 ans
Health Technology
Finance
Consumer Services

Profil

Dr. Douglas D.
Lind
, MD, is a Managing Director at Biomark Capital Management Co. LLC and a Co-President & Director at TMune Therapeutics, Inc. He is on the Board of Directors at TMune Therapeutics, Inc., HyperMed Imaging, Inc. and Lentigen Technology, Inc. Dr. Lind was previously employed as an Independent Director by Enveric Biosciences, Inc., a Managing Director by Burrill & Co. LLC, an Analyst by Morgan Stanley & Co., Inc., a Research Analyst by PaineWebber, Inc., and a Managing Director by GBP Capital.
He also served on the board at Flexible Stenting Solutions, Inc., MabVax Therapeutics, Inc., Opus Bio, Inc., Spectral Image, Inc., Strand Life Sciences Pvt Ltd. and Viragen, Inc. He received his graduate degree from the University of Iowa.

Postes actifs de Douglas Lind

SociétésPosteDébut
President -
Directeur/Membre du Conseil -
Private Equity Investor 01/11/2013
Directeur/Membre du Conseil -

Anciens postes connus de Douglas Lind

SociétésPosteFin
Private Equity Investor 31/10/2013
Directeur/Membre du Conseil 01/02/2005
Analyst-Equity 24/01/2002
Corporate Officer/Principal 31/12/1996
ENVERIC BIOSCIENCES, INC. Directeur/Membre du Conseil -
Voir l'expérience en détail de Douglas Lind

Formation de Douglas Lind

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

93

Relations au 1er degré

16

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées16

Health Technology

Health Technology

Finance

Finance

Finance

Consumer Services

Commercial Services

Technology Services

Finance

Health Technology

Health Services

Health Technology

Health Technology

Finance

Health Technology

Health Technology

  1. Bourse
  2. Insiders
  3. Douglas Lind